Article
Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 1 Jun 2024
Apostolova Carla, Ferroum Amina, Alhassan Basmah, Prakash Ipshita, Basik Mark, Boileau Jean Francois, Martel Karyne, Meterissian Sarkis, Villareal Corpuz Victor, Wong Nora, Foulkes William D, Wong Stephanie M
Abstract excerpt
INTRODUCTION: The impact of timing of genetic testing on uptake of risk reducing mastectomy (RRM) in affected female BRCA1/2 or PALB2 carriers remains an area of evolving interest, particularly with the introduction of mainstream genetic testing initiatives. METHODS: Women with stage I-III breast cancer and a confirmed germline pathogenic variant in BRCA1/2 or PALB2 between 2000 and 2023 were identified from an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
